Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A lung targeted miR-29 mimic as a therapy for pulmonary fibrosis.
Chioccioli M, Roy S, Newell R, Pestano L, Dickinson B, Rigby K, Herazo-Maya J, Jenkins G, Ian S, Saini G, Johnson SR, Braybrooke R, Yu G, Sauler M, Ahangari F, Ding S, DeIuliis J, Aurelien N, Montgomery RL, Kaminski N. Chioccioli M, et al. Among authors: pestano l. EBioMedicine. 2022 Nov;85:104304. doi: 10.1016/j.ebiom.2022.104304. Epub 2022 Oct 17. EBioMedicine. 2022. PMID: 36265417 Free PMC article.
Efficiency and Target Derepression of Anti-miR-92a: Results of a First in Human Study.
Abplanalp WT, Fischer A, John D, Zeiher AM, Gosgnach W, Darville H, Montgomery R, Pestano L, Allée G, Paty I, Fougerousse F, Dimmeler S. Abplanalp WT, et al. Among authors: pestano l. Nucleic Acid Ther. 2020 Dec;30(6):335-345. doi: 10.1089/nat.2020.0871. Epub 2020 Jul 20. Nucleic Acid Ther. 2020. PMID: 32707001 Clinical Trial.
Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo.
Anastasiadou E, Seto AG, Beatty X, Hermreck M, Gilles ME, Stroopinsky D, Pinter-Brown LC, Pestano L, Marchese C, Avigan D, Trivedi P, Escolar DM, Jackson AL, Slack FJ. Anastasiadou E, et al. Among authors: pestano l. Clin Cancer Res. 2021 Feb 15;27(4):1139-1149. doi: 10.1158/1078-0432.CCR-20-3139. Epub 2020 Nov 18. Clin Cancer Res. 2021. PMID: 33208342 Free PMC article.
A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy.
Ramanathan RK, Stephenson JJ, Weiss GJ, Pestano LA, Lowe A, Hiscox A, Leos RA, Martin JC, Kirkpatrick L, Richards DA. Ramanathan RK, et al. Among authors: pestano la. Invest New Drugs. 2012 Aug;30(4):1591-6. doi: 10.1007/s10637-011-9739-9. Epub 2011 Aug 24. Invest New Drugs. 2012. PMID: 21863237 Clinical Trial.
A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination.
Ramanathan RK, Abbruzzese J, Dragovich T, Kirkpatrick L, Guillen JM, Baker AF, Pestano LA, Green S, Von Hoff DD. Ramanathan RK, et al. Among authors: pestano la. Cancer Chemother Pharmacol. 2011 Mar;67(3):503-9. doi: 10.1007/s00280-010-1343-8. Epub 2010 May 12. Cancer Chemother Pharmacol. 2011. PMID: 20461382 Clinical Trial.